ABSTRACT: To identify special metabolites in synovial fluid of osteoarthritis (OA) via a metabolomics approach. Synovial fluid of 35 participants (25 OA patients and 10 controls) was detected by GC-TOF/MS and multivariate data analysis was applied to analyze correlation among the observations. Different metabolites were screened by VIP value (VIP > 1), student t-test (p < 0.05), and fold change (fold >1.5), and verified with the standard metabolites in the synovial fluid of 24 OA patients and 11 controls by LC/MS. The classification performance of different metabolites was analyzed by receiver operating characteristic (ROC) analysis. The results showed that six different metabolites (glutamine, 1,5-anhydroglucitol, gluconic lactone, tyramine, threonine, and 8-aminocaprylic acid) were strongly associated with OA in global metabolomics. Verified results of the first three metabolites were the same as the identified results using targeted metabolomics. ROC curve analysis demonstrated that their concentrations in synovial fluid were strongly correlated to OA. In addition, the concentrations of gluconic lactone were significantly different between OA and RA. Metabolites with altered levels may be contributors to OA pathogenesis and can be used as potential diagnosis criteria for OA. Gluconic lactone may prove to be a novel criterion for differential diagnosis of OA from RA. ß
Osteoarthritis (OA) is the most prevalent form of arthritis and the leading cause of disability. It is well recognized as a multifactorial degenerative joint disease with progressive loss of articular cartilage, joint space narrowing, osteophyte formation, subchondral sclerosis, and synovial inflammation resulting in clinical symptoms such as pain and joint stiffness. 1 The exact pathogenesis of OA remains unknown although genetic and environmental factors, including age, gender, obesity, ethnicity, inherited susceptibility, sports and physical activity, and muscle weakness have been shown to predispose patients to the development of OA. 2 The current methods for diagnosing OA progression are mainly based on radiographic findings; however, radiography only provides structural information of the impaired bone and cartilage rather than pathophysiological information associated with different phenotypes that have been clinically manifested. Altered joint metabolism may be a contributor to OA pathogenesis, and a new phenotype known as "metabolic OA" is gathering more attention in the research community. 3 Metabolites are the end products of cellular processes and their levels can be regarded as a good tool for the diagnosis of OA. 4 Metabolomics has been used as a tool in the study of disease pathogenesis and disease diagnosis due to researchers' ability to quantitatively detect a large number of small-molecule metabolites in body fluids or tissues, making it suitable for researching the great heterogeneity diseases, such as OA. Because of the invasive and large-scale nature, urine samples are widely used for the metabolomics study of OA with 1 H nuclear magnetic resonance (NMR) spectroscopy 5, 6 and gas chromatography followed by mass spectrometry (GC-MS). 7, 8 In addition, serum samples are also used for comparative metabolomics study of OA. 9 Synovial fluid (SF) is a viscous, non-Newtonian fluid that exists in synovial joint cavities, provides nutrients to the articular cartilage, and lubricates the cartilage surfaces. Metabolic products in synovial fluid may reflect the activity of surrounding synovial tissue, bones, and cartilage, thus enabling us to understand the process of OA and identify the specific diagnostic criteria for OA. [10] [11] [12] Mass spectroscopy has an intrinsic high sensitivity for detection, making it an important method for measuring metabolites in complex biofluids. 13 In the present study, we used a GC-TOF/MS combination with multivariate statistical analysis to analyze the global changes in SF metabolites between OA patients and the control group, then we made a comparison between OA metabolites and our former RA metabolites data.
14 LC-MS followed by ROC curve determination was used to verify the identified different metabolites between OA and the control or OA and RA. We attempted to explore the special metabolites of OA, which might assist us in understanding the pathogenesis and diagnosis of OA more deeply.
METHODS

Patient Information
Knee synovial fluid was obtained from 49 OA patients (25 patients who underwent joint replacement surgery (K/L 4) for identification by GC-MS and 24 stage II patients for verification by LC-MS) and 21 normal subjects (10 for identification by GC-MS and 11 for verification by LC-MS) of high amputation. The Guidelines of the Chinese Rheumatology Association (CRA) 2010 edition, which was revised by the Guidelines of American College of Rheumatology (ACR) in 1995, was used for the medical management of osteoarthritis. The clinical details of the OA patients are shown in Supplementary Table S1 . Knee synovial fluid was collected from 50 RA patients for verification by LC-MS. The diagnosis of RA fulfilled 1987 American College of Rheumatology criteria. 15 The clinical details of these patients are shown in Supplementary Table S2A . All samples were collected from Changhai Hospital and Guanghua Special Hospital (Shanghai, China). Samples were centrifuged and stored at À80˚C until analysis. This study was approved by the Shanghai Changhai Hospital Ethics Committee and written informed consent was obtained from all of the participants.
Sample Treatment
We mixed 100 ml of individual knee synovial fluid and 50 ml of L-2-chlorophenylalanine (internal standard) (Shanghai Hengbai Chemical Agents Co., Ltd.) in a new tube; they were extracted and deproteinized by 0.35 ml of methanol, then centrifuged at 10,000 rpm for 10 min at 4˚C. Then the supernatant was collected. The supernatant was be used directly for the samples for LC-MS/MS analysis. For the samples for GC-TOF/MS analysis, the supernatant was completely dried in a vacuum concentrator and then incubated in 80 ml of methoxamine hydrochloride diluted with pyridine to 20 mg/ml at 37˚C for 2.5 h. We then added 100 ml of N,O-bis(trimethylsilyl)trifluoroacetamide (Regis, Morton Grove, IL) containing 1% trimethylchlorosilane (v/v), and incubated at 70˚C for 1 h, then the sample was analyzed by GC-TOF/MS. 16 Unless otherwise specified, all reagents were analytical and purchased from Sinopharm Chemical Reagent Co., Ltd.
GC-TOF/MS Analysis and Data Analysis
Derivative metabolite samples were analyzed by an Agilent 7890 gas chromatograph system (Agilent, Santa Clara, CA) coupled with a Pegasus 4-D time-of-flight mass spectrometer (LECO). A 1 ml aliquot of the samples was injected into a DB-5MS capillary column coated with 5% diphenyl crosslinked with 95% dimethylpolysiloxane (30 m Â 250 mm diameter, 0.25 mm thickness) (J&W Scientific, Beijing, China) for GC separation. Helium was used as the carrier gas and the flow rate through the column was 1 ml/min. The initial temperature was kept at 90˚C for 2 min, then raised to 180˚C at a rate of 5˚C/min, and finally to 285˚C at a rate of 15˚C/min. The temperature for injection, the transfer line, and the ion source was 280, 270, and 220˚C, respectively. The energy was À70 eV in electron impact mode. The mass spectrometry data were acquired in full-scan mode with the m/z range of 20-600 at a rate of 100 spectra/s after a solvent delay of 492 s.
Software Chroma TOF 4.3X (LECO, Saint Joseph, MI) was used to align the metabolite by spectral match (!600) and retention time match (<6 s). Missing data were imputed by half of the minimal spectrum area. 17 Then, metabolite spectra were standardized with the spectrum area of the internal standard. Sample OA14 was excluded from the analysis because of its different metabolite spectra. The standardized data were entered using the SIMCA-P 11.0 software package (Umetrics, Umea, Sweden) for the principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The model of OPLS-DA was validated by a default 7-round crossvalidation procedure with exclusion of 1/7th samples in each round. At the same time, the variable importance for projection (VIP) value of each metabolite in the model was calculated to indicate its contribution to the classification.
When the mass spectral similarity between its peak and mass spectral database was larger than 700 (a similarity over 1,000 means exact match), metabolites were named by TurboMass 4.1.1 software (PerkinElmer Inc.) coupled with the NIST mass spectra database and the LECO mass spectra database. 7 If several peaks had the same name, only the peak with the highest similarity was used. A heat map was generated by PermutMatrix EN software. 18 The data from individual samples (including normal and OA) was divided by the mean of normal samples. Then, the logarithm of metabolites data of samples to base 10 was used for heat map generation.
Metabolites of VIP > 1, fold > 1.5, and p < 0.05 were identified as different metabolites between OA patients and normal subjects. In addition, these different metabolites between OA and the control were compared to our former RA metabolites data 14 and the difference between the OA and RA groups were identified with p < 0.05. The clinical details of the RA patients are shown in Supplementary Table S2B .
LC-MS/MS Analysis and Data Analysis
Different metabolites in endogenous synovial fluid were quantitated using an ACQUITY UPLC H-class coupled with a XEVO G2 QTOFMS with Quant of technology (Waters Corp, Milford, MA). Standard calibration curves were made using authentic standards, which were purchased from Sigma-Aldrich (Glutamine: 76523, 1,5-anhydroglucitol: A7165, and gluconic lactone: G2164). In brief, a 5 ml aliquot of the deproteinized sample was injected into a Waters ACQUITY UPLC system. A reverse-phase 50 Â 2.1 mm, ACQUITY 1.7 mm of BEH, C18 column (Waters Corp) was used to separate chemical components in synovial fluid. To avoid artifacts based on the sample injection order, the order was randomized. Blank and standard samples were injected after every five samples. Technical replication was done thrice for each sample. The samples were quantitated using TargetLynx software (Waters Corp) by peak areas of extracted ion chromatograms. The concentration of each metabolite was calculated from the normalized peak area using the standard calibration plot. The receiver operating characteristic (ROC) curve is an important statistical technique that is created by plotting the sensitivity (also known as the true positive rate) against the false positive rate (1-specificity) at various threshold settings. 19 The area under the ROC curve (AUC) is equal to the probability that reflects the overall diagnostic accuracy of a certain index in
the diagnosis of diseases: 0.5 < AUC 0.7 means low diagnostic accuracy, 0.7 < AUC 0.9 means medium diagnostic accuracy, and 0.9 < AUC <1.0 means high diagnostic accuracy. 20 GraphPad Prism 6 (GraphPad, La Jolla, CA) was used for ROC analysis.
Statistical Analysis
Statistical analysis was performed using SPSS software version 19.0 (SPSS, Chicago, IL). 7 The Shapiro-Wilk method and histograms were used to test if the data were normally distributed and the Levene method was used to test homogeneity of variance. Two sets of data that met the normal distribution and homogeneity of variance were analyzed by unpaired Student's t-test and Fisher's exact test to determine which mean value was significantly different (p < 0.05). The Kruskal-Wallis and Mann-Whitney method of non-parametric testing was used to compare inter-assay differences of the data that did not meet the normal distribution or the homogeneity of variance.
RESULTS
Glutamine Alone or the Combination of Gluconic Lactone and 1,5-Anhydroglucitol as Special Metabolites of OA From Normal Subjects The metabolite profile of OA patients and the control group is different. The chromatogram of a typical human synovial fluid sample showed the extensive complexity of synovial fluid compounds and the compound difference between OA patients and normal subjects ( Supplementary Fig. S1 ). We used GC-MS to acquire 172 peaks; a list of mean values and standard deviations for all identified metabolites is provided in Supplementary Table S3 . Based on the full metabolic data set, two principal components were identified by PCA analysis, and all samples from OA patients were evidently separated from the normal group by OPLS-DA analysis with a high R 2 Y value (0.968) and a Q 2 Y value (0.845) (Fig. 1) . Of 172 peaks, 81 metabolites were named (Fig.  2) . The concentrations of six metabolites were significantly different between the OA patients and the normal subjects, including glutamine, 1,5-anhydroglucitol, gluconic lactone, tyramine, threonine, and 8-aminocaprylic acid (Table 1 ). The detection rate of last three identified differential metabolites (tyramine, threonine, and 8-aminocaprylic acid) was too low to be detected. Among the three other identified differential metabolites, the concentration of glutamine was lower in the synovial fluid from OA patients than in the normal synovial fluid, but the concentrations of 1,5-anhydroglucitol and gluconic lactone were higher in the OA samples than in normal ones.
In order to verify the correlation of the different metabolites to OA, a targeted metabolomics study was adopted to verify glutamine, 1,5-anhydroglucitol, and gluconic lactone in synovial fluid in 24 stage II OA patients and 11 normal subjects. The LC-MS/MS results of the three metabolites were the same as the previously identified results (Fig. 3) . ROC curve analysis showed that all three of the different metabolites had an AUC value within the range of 0.85-0.93 (Fig. 3) . AUC of SF glutamine was 0.929, which can effectively differentiate OA patients from healthy controls. A cutoff value of glutamine (0.087 mmol/L) diagnosed OA at a sensitivity of 91.3% and a specificity of 90.9%. Then, combined metabolites were analyzed by binary logistic regression, followed by ROC curve determination. The results showed that a panel of metabolites (1,5-anhydroglucitol and gluconic lactone) had an AUC of 0.968. Sensitivity and specificity of combined metabolites, which were calculated at best cut-off points, reached 91.3% and 90.9%, respectively. These data implied that combining two metabolites improves sensitivity and could help identify those patients who missed the diagnosis of OA by determination of a single metabolite alone (Fig. 3) .
Gluconic Lactone as a Potential Criterion of OA From RA For identification of different metabolites in the OA and RA patients, we compared different metabolites from OA and control subjects to our former RA metabolites data 14 ; the concentrations of threonine, glutamine, 1,5-anhydroglucitol, and gluconic lactone were significantly different between the OA and RA groups (p < 0.05, 1.5-fold). In addition, the concentrations of gluconic lactone were significantly different between the RA and control groups ( Table 1) .
The targeted metabolomics study was also used to confirm the different metabolites in synovial fluid from OA patients, normal controls, and RA patients with LC-MS/MS analysis. The results showed that the AUC of OA-control, RA-control, and OA-RA was 0.878, 0.798, and 0.936, respectively. The cutoff value of 1.15 mmol/L was used to diagnose RA from the control at a sensitivity of 73.9% and a specificity of 90.9%; and the cutoff value of 1.71 mmol/L was used to differentially diagnose OA from RA and control at the sensitivity and the specificity of 91.3% (Fig. 4) . The concentration of gluconic lactone seems to be a desirable criterion for differential diagnosis of OA from RA. Figure 2 . Heat map of metabolic patterns seen in synovial fluid from OA patients and healthy controls (N). The red indicates that the metabolite is increased compared to the control group; the green indicates that it is decreased; the gray means a failed identification. Metabolites are sorted according to the initial letter. The concentrations of 8-aminocaprylic acid, glutamine, and tyramine were lower in OA patients while the concentrations of 1,5-anhydroglucitol, gluconic lactone, and threonine were higher in OA patients.
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DISCUSSION
Osteoarthritis is one of the most prevalent musculoskeletal arthropathies worldwide in the elderly 21 and diagnosis of OA is mainly based on radiological imaging 22 ; however, radiography only provides structural information about the impaired bone and cartilage, and cannot provide the pathophysiological information associated with different phenotypes that have been clinically manifested. Metabolites are intermediate or end products of various cellular processes and their levels can serve as a good indicator of the series of biological systems in response to genetic and environmental influences. 23 Identification of special metabolites by metabolomics is of great value in differentiating patients from healthy individuals in clinical settings. In the present study, global and targeted metabolomics were used to identify and discover special metabolites from synovial fluid of patients with osteoarthritis.
We detected 172 metabolite signals from the synovial fluid of OA patients and the healthy controls by GC-TOF/MS. The number of detected metabolites was more than that in the previous study 24, 25 with the higher sensitivity of GC-MS. Based on the full data set, all samples from the OA patients and the controls were roughly separated into OA and control groups by multivariate analysis. Metabolites are intermediate or end products of interconnected cellular processes 26 ; analyzing their concentrations provides an avenue to capture the relationships of their represented cellular processes and biological reactions associated with OA. 23 Altered joint metabolism may be a contributor to OA pathogenesis 3 and different metabolites may be a new phenotype contributor to OA diagnosis.
The concentrations of glutamine, 1,5-anhydroglucitol, and gluconic lactone were significantly different between OA patients and normal subjects. The differences between the OA patients and the normal subjects were verified by targeted metabolomics.
Increased gluconic lactone in the synovial fluid of OA patients may be due to autoxidation induced by high levels of ROS; gluconic lactone was a lactone oxidized derivative of glucose. Lindsay et al. 27 reported monosaccharide might be autoxidized to a reactive ketoaldehyde analogue resulting from the high levels of ROS and ROS has been proven to be present in the synovial capsule of OA, such as NO, the superoxide anion, hydrogen peroxide, peroxynitrite, and hydroxyl radicals. 28 ROS are able to induce cartilage degradation directly by cleaving collagen and aggrecan and activating matrix metalloproteinases (MMP). 29, 30 Oxidative stress is proposed to be an important factor in OA and the accumulation of lipid peroxidation products 31 and nitrotyrosine residues 32 have also been observed in OA cartilage. Additionally, gluconic lactone is a potential glycating agent, which reacts with protein to form a ketoimine 27 and advanced glycation end products have been implicated as a major pathogenic process in leading to some diseases, such as diabetic complications. 33 Glutamine is synthesized from glutamate by incorporating an NH 3 into the carboxyl group, which formed an amide 34 ; it is an important amino acid to maintain the lower NH 3 concentration in blood. 35 Glutamine Figure 3 . The diagnosability of differential metabolites to OA determined by the ROC curve analysis. ROC curve analysis of SF glutamine to differentiate OA patients from healthy controls (N). AUC was 0.929. A cutoff value of glutamine (0.087 mmol/L) diagnosed OA at a sensitivity of 91.3% and a specificity of 90.9%. The cutoff value of SF 1,5-anhydroglucitol (78.3% sensitivity, 81.8% specificity) and gluconic lactone (91.3% sensitivity, 81.8% specificity) in the diagnosis of OA. ROC curve of the combined two metabolites provided an AUC of 0.968, and sensitivities and specificities reached 91.3% and 90.9%, respectively.
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suppressed the expression of inflammatory cytokines and reduced ROS production via activing MKP-1 and inhibiting NF-kB and MAPK pathways. 36 In addition, glutamine protected chondrocytes from heat stress and NO-induced apoptosis. 37 These glutamine effects could be utilized to protect chondrocytes from various forms of stress and prevent the progression of cartilage degeneration in OA. The cytoprotective effect of glutamine could be mediated by various mechanisms. Glutamine is a component of glutathione, which is an essential intracellular antioxidant. During stress loading, exogenous glutamine supplementation has been shown to increase the concentration of glutathione that protects cells from injury. 38, 39 Alternatively, glutamine is a precursor of glucosamine and may upregulate glucosamine synthesis in chondrocytes. 40 Glucosamine inhibits cartilage destruction and promotes biosynthetic activity of chondrocytes 41, 42 ; glutamine has suppressed osteoarthritis (OA) progression in a rat OA model, 43 and supplementation of glutamine could provide a novel therapeutic approach to OA.
1,5-Anhydroglucitol(1,5-AG) is a monosaccharide which is sometimes used as a short-term marker of glycaemia in glycaemic excursions. 44, 45 Due to its competition with other monosaccharides for reabsorption in the proximal renal tubule, the 1,5-AG excretion rate depends on the renal threshold for glucose. 46, 47 In addition, the elevated 1,5-AG concentration in the synovial fluid is consistent with the reduced glucose concentration in the synovial fluid of osteoarthritis patients, which has been proven because of the proliferation and thickening of the knee capsule in OA patients increased the consumption of glucose. 48 Our data indicate that glutamine, 1,5-anhydroglucitol, and gluconic lactone could be potential criteria of OA synovial fluid. Combined metabolites (1,5-anhydroglucitol and gluconic lactone) were more dependable in the diagnosis of OA than those of a single metabolite. This implies that the new diagnostic model combining two metabolites possesses improved sensitivity and could identify those patients who missed the diagnosis of OA by a single metabolite alone. Because complex diseases involve systematic deregulation of biochemical pathways, a panel of multiple criteria rather than a single criterion will have more power to provide clinically useful information for a differential diagnosis. However, because of the difficulty of collecting the knee synovial fluid from early-stages OA patients, only knee synovial fluid obtained from OA patients who had joint replacement surgery was used in our study. Further studies are needed to vary the use of these metabolites as biomarkers of OA, including more patients and earlystage OA patients.
Additionally, ROC curve analysis showed that gluconic lactone is a desired criterion for differential diagnosis of OA from RA. AUC of OA-control, RA-control, and OA-RA were 0.878, 0.798, and 0.936, respectively. The cutoff value of 1.15 mmol/L diagnosed RA at a sensitivity of 73.9% and a specificity of 90.9%; and the cutoff value of 1.71 mmol/L differentially diagnosed OA from RA at the sensitivity and the specificity of 91.3%. Gluconic lactone might be a potential criterion of OA because its concentrations in OA patients, RA patients, and the controls were significantly different, showing a high sensitivity and specificity between them.
CONCLUSIONS
In summary, the present study showed that GC-MS-based global metabolomics and LC-MS-based targeted metabolomics of synovial fluid could help discover special metabolites of OA, which may enable us to understand the pathological mechanism of OA and identify OA from the control. In addition, a panel of multiple metabolites rather than a single metabolite has more power to discriminate OA. Gluconic lactone may prove to be a novel criterion for the differential diagnosis of OA from RA. Our results promise a potential for early diagnosis, therapy monitoring, and understanding the pathogenesis of OA.
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